Le Lézard
Classified in: Health, Business, Sports and recreation
Subjects: NPT, FVT

Media Advisory - Ride for Cancer powered by BMO Bank of Montreal is doing something #BIGGER for cancer care in our region



HALIFAX, Sept. 27, 2017 /CNW/ - 

Logo: Ride for Cancer (CNW Group/QEII Foundation)

 

What: 

On Saturday, September 30, more than 475 riders will embark on an epic journey spanning 130 kilometres from Mahone Bay to Halifax ? all in support of Atlantic Canadians battling cancer. Ride for Cancer powered by BMO Bank of Montreal is Atlantic Canada's largest one-day fundraising cycling event that is hosted in partnership by the QEII Foundation and The Leukemia & Lymphoma Society of Canada. The goal is to raise $500,000 net for local cancer care.



When: 

Interview opportunities: Saturday, September 30 from 4:00 p.m. to 5:00 p.m.  



Where: 

LED Roadway Lighting, 115 Chain Lake Dr., Halifax, N.S. (finish line celebration)



Why: 

Since 2015, Ride for Cancerpowered by BMO Bank of Montreal has raised over $572,000 net to advance cancer care for Atlantic Canadians.




With a goal of raising $500,000 net, funds raised from the 2017 Ride for Cancer powered by BMO Bank of Montreal event will purchase advanced cancer therapy preparation equipment for the QEII Health Sciences Centre, support local blood cancer research, and fund patient and family support through The Leukemia and Lymphoma Society of Canada.



Who:

Riders ? who will complete one of five distance options via the Rum Runners Trail (25, 50 or 100 kilometres) or via road (100 or 130 kilometres) ? volunteers, sponsors, and supporters.

 

SOURCE QEII Foundation


These press releases may also interest you

at 18:34
Blessed Herbs Cafe and Mount Zion Rastafarian Church founder and practicing Rasta George Metropoulos today announced the launch of the organization's first holiday season food and cash drive. Directly benefiting the neighborhood's less fortunate...

at 11:40
A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with axicabtagene ciloleucel, offered commercially under the brand name Yescartatm, remain in remission 15...

at 10:47
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriahtm (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r)...

at 10:30
For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight...

at 08:48
Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality...

at 08:32
The number of variants identified as being associated with cancer risk and progression is rapidly growing. Meanwhile, advances in medical genomics are paving the way to novel approaches for the diagnosis, management, and treatment of patients with...




News published on 27 september 2017 at 13:50 and distributed by: